Roderich E Schwarz

List of Publications by Year
in descending order

54 papers	1,676 citations	331670 21 h-index	276875 41 g-index
55 all docs	55 docs citations	55 times ranked	2793 citing authors

#	Article	IF	Citations
1	Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy. Molecular Cancer Therapeutics, 2022, 21, 1149-1159.	4.1	3
2	Targeted dual inhibition of câ€Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models. Journal of Cellular and Molecular Medicine, 2021, 25, 4950-4961.	3.6	8
3	Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Letters, 2019, 459, 41-49.	7.2	35
4	Therapeutic efficacy of antiâ€MMP9 antibody in combination with nabâ€paclitaxelâ€based chemotherapy in preâ€clinical models of pancreatic cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 3878-3887.	3.6	22
5	Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma. Scientific Reports, 2019, 9, 17608.	3.3	11
6	Physician derived versus administrative data in identifying surgical complications. Fact versus Fiction. American Journal of Surgery, 2019, 217, 447-451.	1.8	5
7	Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma. Translational Oncology, 2018, 11, 426-435.	3.7	21
8	Quality measurement affecting surgical practice: Utility versus utopia. American Journal of Surgery, 2018, 215, 357-366.	1.8	10
9	Clinical trends and effects on quality metrics for surgical gastroesophageal cancer care. Translational Gastroenterology and Hepatology, 2018, 3, 43-43.	3.0	3
10	Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreatic cancer stem cell motility. Biochemical Pharmacology, 2018, 156, 458-466.	4.4	22
11	Augmentation of Nab-Paclitaxel Chemotherapy Response by Mechanistically Diverse Antiangiogenic Agents in Preclinical Gastric Cancer Models. Molecular Cancer Therapeutics, 2018, 17, 2353-2364.	4.1	11
12	Simplicity and Safety: Minimized Pancreatic Fistula Rate after Distal Pancreatectomy through Pancreas Stump Sutured Fish-Mouth Closure. American Surgeon, 2018, 84, 1734-1740.	0.8	2
13	Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget, 2018, 9, 5274-5286.	1.8	24
14	Managing the Unmanageable: A Two-Staged Palliative Resection to Control Life-Threatening Duodenal Bleeding Due to Recurrent Paraganglioma. American Journal of Case Reports, 2018, 19, 386-391.	0.8	2
15	Institutional variants for lymph node counts after pancreatic resections. American Journal of Surgery, 2017, 214, 437-441.	1.8	0
16	A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma. PLoS ONE, 2017, 12, e0171824.	2.5	10
17	Vascular challenges from pancreatoduodenectomy in the setting of coeliac artery stenosis. BMJ Case Reports, 2017, 2017, bcr2016217943.	0.5	3
18	A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. Annals of Surgical Oncology, 2016, 23, 218-224.	1.5	61

#	Article	IF	Citations
19	Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Oncotarget, 2016, 7, 46988-47001.	1.8	10
20	Experience with a simple clamp-crush technique devoid of other devices for liver resections in a surgical oncology practice. American Journal of Surgery, 2015, 209, 503-508.	1.8	1
21	CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Cancer Letters, 2015, 359, 335-343.	7.2	82
22	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Letters, 2015, 358, 59-66.	7.2	48
23	Current Status of Management of Malignant Disease: Current Management of Gastric Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 782-788.	1.7	27
24	Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. Molecular Cancer Therapeutics, 2014, 13, 1032-1043.	4.1	19
25	Biliary obstruction and postoperative morbidity after pancreatoduodenectomy: what still obstructs clearance to clearance of obstruction. American Journal of Surgery, 2014, 208, 11-12.	1.8	0
26	Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1-3 involved para-aortic nodes. Chinese Medical Journal, 2014, 127, 435-41.	2.3	6
27	Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. Hpb, 2013, 15, 106-115.	0.3	44
28	Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis, 2013, 34, 2361-2369.	2.8	107
29	Antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.. Journal of Clinical Oncology, 2013, 31, 33-33.	1.6	1
30	Association of the establishment of multidisciplinary (MDC) hepatocellular carcinoma (HCC) clinic with clinical outcome.. Journal of Clinical Oncology, 2013, 31, 332-332.	1.6	1
31	Comparative benefits of nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 192-192.	1.6	1
32	The efficacy of a novel, dual PI3K/mTOR inhibitor NVPâ€BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. Journal of Cellular Biochemistry, 2012, 113, 784-791.	2.6	78
33	Potential factors to explain decreased survival for ethnic subgroups with gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, 12-12.	1.6	1
34	Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 170-170.	1.6	2
35	Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic Cancer. PLoS ONE, 2012, 7, e38477.	2.5	32
36	Clinical Evidence: Metastases can Metastasize. World Journal of Oncology, 2012, 3, 138-141.	1.5	3

#	Article	IF	Citations
37	Effect of 2G8, a TGF-beta-R2 inhibitor, on TGF-beta signaling and migration in an immunocompetent pancreatic cancer model.. Journal of Clinical Oncology, 2012, 30, 230-230.	1.6	0
38	Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivo.. Journal of Clinical Oncology, 2012, 30, 234-234.	1.6	0
39	Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer, 2011, 11, 15.	2.6	26
40	Challenges with Demographic Disparities in Gastric Cancer Care and Survival: Spectral Rather than Black and White. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 221-222.	2.5	0
41	Transplantation for hepatocellular carcinoma as part of a balanced, multidisciplinary strategy. Oncology, 2011, 25, 761-3.	0.5	0
42	EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer. Annals of Surgical Oncology, 2010, 17, 1442-1452.	1.5	24
43	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. Hpb, 2010, 12, 313-320.	0.3	68
44	Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biology and Therapy, 2010, 9, 632-639.	3.4	32
45	An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery, 2009, 146, 241-249.	1.9	15
46	Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. American Journal of Surgery, 2008, 195, 829-836.	1.8	92
47	Factors influencing change of preoperative treatment intent in a gastrointestinal cancer practice. World Journal of Surgical Oncology, 2007, 5, 32.	1.9	8
48	Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Annals of Surgical Oncology, 2007, 14, 317-328.	1.5	231
49	Lymph Node Dissection Impact on Staging and Survival of Extrahepatic Cholangiocarcinomas, Based on U.S. Population Data. Journal of Gastrointestinal Surgery, 2007, 11, 158-165.	1.7	53
50	Clinical Impact of Lymphadenectomy Extent in Resectable Esophageal Cancer. Journal of Gastrointestinal Surgery, 2007, 11, 1384-1394.	1.7	128
51	Extent of Lymph Node Retrieval and Pancreatic Cancer Survival: Information from a Large US Population Database. Annals of Surgical Oncology, 2006, 13, 1189-1200.	1.5	209
52	Hypomagnesemia after Major Abdominal Operations in Cancer Patients: Clinical Implications. Archives of Medical Research, 2005, 36, 36-41.	3.3	21
53	Complications of Malignancy. Journal of Clinical Oncology, 2004, 22, 373-374.	1.6	5
54	An orthotopic in vivo model of human pancreatic cancer. Surgery, 1999, 126, 562-567.	1.9	48